Français | English

Agence nationale sanitaire et scientifique en cancérologie

Accueil Nota Bene Cancer V2 Numéro 132 du 17 April 2012 Dépistage, diagnostic et pronostic

Print

Nota Bene Cancer Numéro 132 du 17 April 2012 RSS

Dépistage, diagnostic et pronostic

Découverte de technologies et de biomarqueurs

Menée sur 77 patients atteints d'un carcinome rénal à cellules claires, cette étude identifie trois micro-ARNs dont l'expression est associée à la survie sans récidive après une néphrectomie

  • Détails
    Fermer

    Menée sur 77 patients atteints d'un carcinome rénal à cellules claires, cette étude identifie trois micro-ARNs dont l'expression est associée à la survie sans récidive après une néphrectomie

    “Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients”

    • Slaby, Ondrej;Redova, Martina;Poprach, Alexandr;Nekvindova, Jana;Iliev, Robert;Radova, Lenka;Lakomy, Radek;Svoboda, Marek;Vyzula, Rostislav

    Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney. One of the important unmet medical needs in RCC is prognostic biomarker enabling identification of patients at high risk of relapse after nephrectomy. MicroRNAs (miRNAs) constitute a robust regulatory network with posttranscriptional regulatory efficiency for almost one-half of human coding genes, including oncogenes and tumor suppressors. To identify potential prognostic miRNAs, we analyzed expression profiles in tumors of different prognostic groups of RCC patients. Seventy-seven patients with clear cell RCC and detailed clinicopathological data were enrolled in a single-center study. Global miRNA expression profiles were obtained by use of TaqMan Low Density Arrays (754 parallel quantitative reverse-transcriptase polymerase chain reactions (qRT-PCR) reactions). For validation of identified miRNAs individual miRNA TaqMan assays were performed in an independent group of patients. We identified tumor ...


Mots clés : Rein; Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Menée sur un modèle murin, cette étude évalue la faisabilité d'une technique d'imagerie à base d'une nanoparticule pour visualiser les marges d'exérèse de tumeurs cérébrales

  • Détails
    Fermer

    Menée sur un modèle murin, cette étude évalue la faisabilité d'une technique d'imagerie à base d'une nanoparticule pour visualiser les marges d'exérèse de tumeurs cérébrales

    “A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle”

    • Kircher, Moritz F.;de la Zerda, Adam;Jokerst, Jesse V.;Zavaleta, Cristina L.;Kempen, Paul J.;Mittra, Erik;Pitter, Ken;Huang, Ruimin;Campos, Carl;Habte, Frezghi;Sinclair, Robert;Brennan, Cameron W.;Mellinghoff, Ingo K.;Holland, Eric C.;Gambhir, Sanjiv S.

    The difficulty in delineating brain tumor margins is a major obstacle in the path toward better outcomes for patients with brain tumors. Current imaging methods are often limited by inadequate sensitivity, specificity and spatial resolution. Here we show that a unique triple-modality magnetic resonance imaging–photoacoustic imaging–Raman imaging nanoparticle (termed here MPR nanoparticle) can accurately help delineate the margins of brain tumors in living mice both preoperatively and intraoperatively. The MPRs were detected by all three modalities with at least a picomolar sensitivity both in vitro and in living mice. Intravenous injection of MPRs into glioblastoma-bearing mice led to MPR accumulation and retention by the tumors, with no MPR accumulation in the surrounding healthy tissue, allowing for a noninvasive tumor delineation using all three modalities through the intact skull. Raman imaging allowed for guidance of intraoperative tumor resection, and a histological ...


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Menée in vitro et in vivo, cette étude évalue la faisabilité d'une technique d'imagerie permettant de visualiser la mort des cellules du micro-environnement tumoral en réponse à un traitement

  • Détails
    Fermer

    Menée in vitro et in vivo, cette étude évalue la faisabilité d'une technique d'imagerie permettant de visualiser la mort des cellules du micro-environnement tumoral en réponse à un traitement

    “In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single cell resolution”

    • Earley, Sarah;Vinegoni, Claudio;Dunham, Joshua;Gorbatov, Rostic;Fumene Feruglio, Paolo;Weissleder, Ralph

    Observing drug responses in the tumor microenvironment in vivo can be technically challenging. As a result, cellular responses to molecularly targeted cancer drugs are often studied in cell culture, which does not accurately represent the behavior of cancer cells growing in vivo. Using high resolution microscopy and fluorescently labeled genetic reporters for apoptosis, we developed an approach to visualize drug-induced cell death at single cell resolution in vivo. Stable expression of the mitochondrial intermembrane protein IMS-RP was established in human breast and pancreatic cancer cells. Automated image analysis was then used to quantify release of IMS-RP into the cytoplasm upon apoptosis and irreversible mitochondrial permeabilization. Both breast and pancreatic cancer cells showed higher basal apoptotic rates in vivo than in culture. To study drug-induced apoptosis, we exposed tumor cells to navitoclax (ABT-263), an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, both in vitro and in ...


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Cet article passe en revue les enjeux associés à l'usage de biomarqueurs moléculaires pour le dépistage des cancers

  • Screening for cancer with molecular markers: progress comes with potential problems
    Nature Reviews Cancer, sous presse, 2012 (résumé)
    Détails
    Fermer

    Cet article passe en revue les enjeux associés à l'usage de biomarqueurs moléculaires pour le dépistage des cancers

    “Screening for cancer with molecular markers: progress comes with potential problems”

    • Baron, John A.

    Recent research has raised hopes for impressively accurate screening for cancer with molecular biomarkers. These molecular markers will probably be more sensitive and specific than older screening modalities, as well as easier to use. In this Essay, I argue that these sensitive screening tests might be clinically valuable — but that they will present unique issues in implementation and interpretation. These issues are likely to affect the way clinicians conduct screening and the way that they make diagnoses in individuals who screen positive for cancer.


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Découverte de technologies et de biomarqueurs)

Evaluation des technologies et des biomarqueurs

Menée sur des échantillons tumoraux prélevés sur 1 286 patientes atteintes d'un cancer du sein HER2+ non métastatique, cette étude évalue l'association entre des polymorphismes à simple nucléotide des récepteurs FCGR3A-V/F et FCGR2A-H/R et la réponse au trastuzumab

  • Détails
    Fermer

    Menée sur des échantillons tumoraux prélevés sur 1 286 patientes atteintes d'un cancer du sein HER2+ non métastatique, cette étude évalue l'association entre des polymorphismes à simple nucléotide des récepteurs FCGR3A-V/F et FCGR2A-H/R et la réponse au trastuzumab

    “Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients”

    • Hurvitz, Sara A;Betting, David J;Stern, Howard M.;Quinaux, Emmanuel;Stinson, Jeremy;Seshagiri, Somasekar;Zhao, Ying;Buyse, Marc;Mackey, John R.;Driga, Adrian;Damaraju, Sambasivarao;Sliwkowski, Mark X.;Robert, Nicholas J;Valero, Vicente;Crown, John;Falkson, Carla I;Brufsky, Adam M;Pienkowski, Tadeusz;Eiermann, Wolfgang;Martin, Miguel;Bee, Valerie;Marathe, Omkar;Slamon, Dennis J.;Timmerman, John M

    Purpose: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcgamma receptors (FcgammaR) on leukocytes may contribute to its anti-tumor effects. Single nucleotide polymorphisms (SNPs) in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131 respectively and affect binding of antibodies to FcgammaR such that 158V/V and 131H/H bind with highest affinity. This study aimed to determine whether high affinity SNPs are associated with disease free survival (DFS) among patients with HER2-positive non-metastatic breast cancer. Experimental Design: Genomic DNA was isolated from 1,286 patients enrolled in a trial of adjuvant trastuzumab-based chemotherapy. Genotyping was performed using Sanger sequencing and Sequenom mass spectrometry. Results: 1,189 patient samples were successfully genotyped for FCGR3A and 1,218 for FCGR2A. Compared to the overall results of the ...


Mots clés : Sein; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

A partir de données portant sur 511 patientes atteintes d'un cancer de l'ovaire, cette étude évalue l'intérêt d'une signature basée sur l'expression de 23 gènes pour prédire la réponse à un traitement à base de sels de platine

  • A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
    Journal of the National Cancer Institute, sous presse, 2012 (article en libre accès)
    Détails
    Fermer

    A partir de données portant sur 511 patientes atteintes d'un cancer de l'ovaire, cette étude évalue l'intérêt d'une signature basée sur l'expression de 23 gènes pour prédire la réponse à un traitement à base de sels de platine

    “A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy”

    • Kang, Josephine;D’Andrea, Alan D.;Kozono, David

    Background New tools are needed to predict outcomes of ovarian cancer patients treated with platinum-based chemotherapy. We hypothesized that a molecular score based on expression of genes that are involved in platinum-induced DNA damage repair could provide such prognostic information.Methods Gene expression data was extracted from The Cancer Genome Atlas (TCGA) database for 151 DNA repair genes from tumors of serous ovarian cystadenocarcinoma patients (n = 511). A molecular score was generated based on the expression of 23 genes involved in platinum-induced DNA damage repair pathways. Patients were divided into low (scores 0–10) and high (scores 11–20) score groups, and overall survival (OS) was analyzed by Kaplan–Meier method. Results were validated in two gene expression microarray datasets. Association of the score with OS was compared with known clinical factors (age, stage, grade, and extent of surgical debulking) using univariate and multivariable Cox proportional ...


  • Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time
    Journal of the National Cancer Institute, sous presse, 2012 (éditorial en libre accès)
    Détails
    Fermer

    A partir de données portant sur 511 patientes atteintes d'un cancer de l'ovaire, cette étude évalue l'intérêt d'une signature basée sur l'expression de 23 gènes pour prédire la réponse à un traitement à base de sels de platine

    “Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time”

    • Swisher, Elizabeth M. ; Taniguchi, Toshiyasu ; Karlan, Beth Y.

    Ovarian carcinoma has the highest mortality of all gynecological cancers. The American Cancer Society estimates that in 2012, about 22 280 new cases of ovarian cancer will be diagnosed, and 15 500 women will die of ovarian cancer in the United States (1). Despite achieving high rates of remission following radical surgery and platinum-based chemotherapy, most women relapse and ultimately die of chemoresistant disease. Advances in chemotherapy lengthen survival for women with advanced-stage (stages III and IV) disease but have not changed the likelihood of cure. Biomarkers, such as the rate of decline of serum cancer antigen 125 (CA-125, also known as mucin-16) level or the absolute CA-125 nadir, can be predictors of progression-free and overall survivals (2–4); however, when faced with a slowly declining level of CA-125 during primary treatment, the oncologist has few effective alternatives. With almost 80% of primary ovarian cancers initially responding to platinum-based ...


Mots clés : Ovaire; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 90 patients atteints d'un cancer colorectal, puis à partir de données portant sur des patients atteints d'autres types de cancer, cette étude suggère qu'une surexpression de CD133 ne reflète pas un nombre élevé de cellules souches cancéreuses mais est associée à des mutations des gènes K-RAS ou B-RAF

  • Mutations in the Ras-Raf axis underlie the prognostic value of CD133 in colorectal cancer
    Clinical Cancer Research, sous presse, 2012 (résumé)
    Détails
    Fermer

    Menée sur 90 patients atteints d'un cancer colorectal, puis à partir de données portant sur des patients atteints d'autres types de cancer, cette étude suggère qu'une surexpression de CD133 ne reflète pas un nombre élevé de cellules souches cancéreuses mais est associée à des mutations des gènes K-RAS ou B-RAF

    “Mutations in the Ras-Raf axis underlie the prognostic value of CD133 in colorectal cancer”

    • Kemper, Kristel;Versloot, Miranda;Cameron, Kate;Colak, Selcuk;Bleakley, Joanne;Vermeulen, Louis;de Sousa e Melo, Felipe;Versteeg, Rogier;de Jong, Joan H.;Koster, Jan;Medema, Jan Paul

    Purpose High expression of cancer stem cell (CSC) marker CD133 has been used as a predictor for prognosis in colorectal cancer (CRC), suggesting that enumeration of CSCs, using CD133, is predictive for disease progression. However, we showed recently that both CD133 mRNA and protein are not downregulated during differentiation of colon CSCs, pointing to an alternative reason for the prognostic value of CD133. We therefore set out to delineate the relation between CD133 expression and prognosis. Experimental design A CRC patient series was studied for expression of CD133 and other CSC markers by microarray and qPCR analysis. Additionally, several common mutations were analyzed to determine the relation with CD133 expression. Results CD133 mRNA expression predicted relapse-free survival in our patient series, while several other CSC markers could not. Moreover, no correlation was found between expression of other CSC markers and CD133. Interestingly, high CD133 expression was related to ...


Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Menée sur 285 patients atteints d'un cancer colorectal de stade II ou III et recevant une chimiothérapie adjuvante à base de fluorouracile, cette étude évalue l'association entre 26 polymorphismes à simple nucléotide, récemment identifiés dans des études d'association sur le génome entier, et le risque de récidive de la maladie

  • Détails
    Fermer

    Menée sur 285 patients atteints d'un cancer colorectal de stade II ou III et recevant une chimiothérapie adjuvante à base de fluorouracile, cette étude évalue l'association entre 26 polymorphismes à simple nucléotide, récemment identifiés dans des études d'association sur le génome entier, et le risque de récidive de la maladie

    “GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes”

    • Dai, Jingyao;Gu, Jian;Huang, Maosheng;Eng, Cathy;Kopetz, E. Scott;Ellis, Lee M.;Hawk, Ernest;Wu, Xifeng

    Recent genome-wide association studies (GWAS) have identified several common susceptibility loci associated with the risk of colorectal cancer (CRC). However, whether these loci affect clinical outcomes of CRC is not clear. In this study, we genotyped 26 single nucleotide polymorphisms (SNPs) in ten GWAS-identified CRC susceptibility regions and evaluated their associations with survival and recurrence in 285 stage II and III patients receiving fluorouracil-based adjuvant chemotherapy. Only one SNP, rs10318 (15q13.3), was significantly associated with recurrence for patients with stage II disease. Three SNPs: rs10749971 (11q23.1), rs961253 (20p12.3), and rs355527 (20p12.3) in two regions were significantly associated with recurrence for patients with stage III disease. Five SNPs: rs961253 (20p12.3), rs355527 (20p12.3), rs4464148 (18q21.1), rs6983267 (8q24.21), and rs10505477 (8q24.21) in three regions were significantly associated with survival for patients with stage III disease. ...


Mots clés : Colon-rectum; Dépistage, diagnostic et pronostic (Evaluation des technologies et des biomarqueurs)

Essais de technologies et de biomarqueurs dans un contexte clinique

A partir de données cliniques portant sur 753 patientes atteintes d'un cancer de l'endomètre de stade précoce et ayant subi une hystérectomie totale par laparoscopie ou par voie ouverte, cet essai randomisé identifie les facteurs de risque permettant de prédire la survenue d'événements postopératoires indésirables

  • Détails
    Fermer

    A partir de données cliniques portant sur 753 patientes atteintes d'un cancer de l'endomètre de stade précoce et ayant subi une hystérectomie totale par laparoscopie ou par voie ouverte, cet essai randomisé identifie les facteurs de risque permettant de prédire la survenue d'événements postopératoires indésirables

    “Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial”

    • Kondalsamy-Chennakesavan, Srinivas;Janda, Monika;Gebski, Val;Baker, Jannah;Brand, Alison;Hogg, Russell;Jobling, Thomas W.;Land, Russell;Manolitsas, Tom;Nascimento, Marcelo;Neesham, Deborah;Nicklin, James L.;Oehler, Martin K.;Otton, Geoff;Perrin, Lewis;Salfinger, Stuart;Hammond, Ian;Leung, Yee;Sykes, Peter;Ngan, Hextan;Garrett, Andrea;Laney, Michael;Ng, Tong Yow;Tam, Karfai;Chan, Karen;Wrede, David H.;Pather, Selvan;Simcock, Bryony;Farrell, Rhonda;Robertson, Gregory;Walker, Graeme;McCartney, Anthony;Obermair, Andreas

    Aims To identify risk factors for major adverse events (AEs) and to develop a nomogram to predict the probability of such AEs in patients who have surgery for apparent early stage endometrial cancer. Methods We used data from 753 patients who were randomised to either total laparoscopic hysterectomy or total abdominal hysterectomy in the LACE trial. Serious adverse events that prolonged hospital stay or postoperative adverse events (using common terminology criteria 3+, CTCAE V3) were considered major AEs. We analysed pre-surgical characteristics that were associated with the risk of developing major AEs by multivariate logistic regression. We identified a parsimonious model by backward stepwise logistic regression. The six most significant or clinically important variables were included in the nomogram to predict the risk of major AEs within 6 weeks of surgery and the nomogram was internally validated. Results Overall, 132 (17.5%) patients had at least one major AE. An open ...


Mots clés : Utérus (autre); Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

A partir de données clinico-pathologiques portant sur 378 patients atteints d'un carcinome métastatique à cellules rénales et ayant subi une néphrectomie cytoréductive, cette étude évalue l'intérêt et les limites de biopsies préopératoires à l'aiguille pour identifier des caractéristiques pathologiques à haut risque

  • Détails
    Fermer

    A partir de données clinico-pathologiques portant sur 378 patients atteints d'un carcinome métastatique à cellules rénales et ayant subi une néphrectomie cytoréductive, cette étude évalue l'intérêt et les limites de biopsies préopératoires à l'aiguille pour identifier des caractéristiques pathologiques à haut risque

    “Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases”

    • Abel, E. Jason;Carrasco, Alonso;Culp, Stephen H.;Matin, Surena F.;Tamboli, Pheroze;Tannir, Nizar M.;Wood, Christopher G.

    What's known on the subject ? and What does the study add ? Although there have been many investigations of biopsy for small renal masses, there are scant data on the accuracy of biopsy in the setting of metastatic renal cell carcinoma (mRCC). We report a large series of biopsies and compare with nephrectomy pathology in patients with mRCC. The present study highlights the inaccuracy of biopsy in the setting of metastatic disease, which is related to sampling error because of heterogeneity within the tumour and among metastases. These limitations are important to realize when designing trials that depend on pathological findings from biopsy and not nephrectomy. In addition, we found that biopsy of primary tumours were more likely than biopsy of metastatic sites to be diagnostic of RCC. Future studies with multiquadrant biopsies of primary tumours could yield the most accurate pathological results for future studies. OBJECTIVE : To evaluate the ability of preoperative biopsy to ...


Mots clés : Rein; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée à partir d'échantillons tumoraux prélevés sur 94 patients atteints d'un cancer localisé de la prostate et ayant subi une prostatectomie radicale (durée médiane de suivi : 11,7 ans), cette étude évalue l'association entre l'expression de 8 protéines de la matrice nucléaire, le risque d'augmentation du niveau de l'antigène prostatique spécifique et le risque de décès

  • Prognostic value of nuclear matrix protein expression in localized prostate cancer
    Journal of Cancer Research and Clinical Oncology, sous presse, 2012 (résumé)
    Détails
    Fermer

    Menée à partir d'échantillons tumoraux prélevés sur 94 patients atteints d'un cancer localisé de la prostate et ayant subi une prostatectomie radicale (durée médiane de suivi : 11,7 ans), cette étude évalue l'association entre l'expression de 8 protéines de la matrice nucléaire, le risque d'augmentation du niveau de l'antigène prostatique spécifique et le risque de décès

    “Prognostic value of nuclear matrix protein expression in localized prostate cancer”

    • Ricci, Francesco;Rubagotti, Alessandra;Zinoli, Linda;Mangerini, Rosa;Nuzzo, Pier;Carmignani, Giorgio;Simonato, Alchiede;Barboro, Paola;Balbi, Cecilia;Boccardo, Francesco

    Purpose The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa). Methods High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to each cluster were constructed by means of the Kaplan–Meier method and curves compared by the log-rank test. Multi-parametric models were constructed according to Cox proportional hazard technique. Results After a median follow-up of 11.7 years (range, 6.5–16.2), 50 patients ...


Mots clés : Prostate; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 98 patients atteints d'un cancer du poumon traité par radiothérapie conventionnelle fractionnée, cette étude compare la précision et la couverture tumorale de deux protocoles de tomographie numérique, l'un utilisant la colonne vertébrale comme point de repère, l'autre la carène

  • Volumetric Image Guidance Using Carina vs Spine as Registration Landmarks for Conventionally Fractionated Lung Radiotherapy
    International journal of radiation oncology, biology, physics, sous presse, 2012 (résumé)
    Détails
    Fermer

    Menée sur 98 patients atteints d'un cancer du poumon traité par radiothérapie conventionnelle fractionnée, cette étude compare la précision et la couverture tumorale de deux protocoles de tomographie numérique, l'un utilisant la colonne vertébrale comme point de repère, l'autre la carène

    “Volumetric Image Guidance Using Carina vs Spine as Registration Landmarks for Conventionally Fractionated Lung Radiotherapy”

    • Lavoie, Caroline;Higgins, Jane;Bissonnette, Jean-Pierre;Le, Lisa W.;Sun, Alexander;Brade, Anthony;Hope, Andrew;Cho, John;Bezjak, Andrea

    To compare the relative accuracy of 2 image guided radiation therapy methods using carina vs spine as landmarks and then to identify which landmark is superior relative to tumor coverage. For 98 lung patients, 2596 daily image-guidance cone-beam computed tomography scans were analyzed. Tattoos were used for initial patient alignment; then, spine and carina registrations were performed independently. A separate analysis assessed the adequacy of gross tumor volume, internal target volume, and planning target volume coverage on cone-beam computed tomography using the initial, middle, and final fractions of radiation therapy. Coverage was recorded for primary tumor (T), nodes (N), and combined target (T+N). Three scenarios were compared : tattoos alignment, spine registration, and carina registration. Spine and carina registrations identified setup errors ≥5 mm in 35% and 46% of fractions, respectively. The mean vector difference between spine and carina matching had a magnitude of 3.3 ...


Mots clés : Poumon; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 107 patients atteints d'un carcinome épidermoïde de l'œsophage localement avancé et ayant reçu une chimioradiothérapie suivie d'une résection tumorale complète (durée médiane de suivi supérieure à 6 ans), cette étude évalue l'intérêt des résultats histopathologiques pour prédire la survie à long terme et le contrôle local de la maladie

  • Détails
    Fermer

    Menée sur 107 patients atteints d'un carcinome épidermoïde de l'œsophage localement avancé et ayant reçu une chimioradiothérapie suivie d'une résection tumorale complète (durée médiane de suivi supérieure à 6 ans), cette étude évalue l'intérêt des résultats histopathologiques pour prédire la survie à long terme et le contrôle local de la maladie

    “Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus”

    • Stahl, Michael;Lehmann, Nils;Walz, Martin K.;Stuschke, Martin;Wilke, Hansjochen

    Background : Due to the poor prognosis of locally advanced oesophageal cancer, predictive markers are warranted to better select patients who may benefit from multimodal therapy. Patients and methods : Patients with oesophageal cancer from two multicentric prospective trials were selected for having received radiochemotherapy followed by macroscopic complete tumour resection. Several pretreatment and treatment related factors were retrospectively analysed for their ability to serve as predictive markers. Results : Overall 107 patients with squamous cell carcinomas stage T3-4 N and M0 were included in the analysis. All of them had complete preoperative radiochemotherapy. Microscopic (n = 96) or macroscopic (N = 11) complete resection was achieved by transthoracic oesophagectomy. The median follow-up time exceeded 6 years. Local progression free and overall survival were significantly hampered in patients with residual tumour in their resected specimen (n = 76) compared with patients ...


Mots clés : Oesophage; Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Menée sur 120 patients atteints de carcinomes d'origine inconnue, cette étude évalue la sensibilité, la spécificité et la précision d'une tomographie numérique utilisant le 18-fluorodésoxyglucose et couvrant la totalité du corps pour détecter et identifier la tumeur primitive occulte

  • Détails
    Fermer

    Menée sur 120 patients atteints de carcinomes d'origine inconnue, cette étude évalue la sensibilité, la spécificité et la précision d'une tomographie numérique utilisant le 18-fluorodésoxyglucose et couvrant la totalité du corps pour détecter et identifier la tumeur primitive occulte

    “Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary”

    • Han, Anqin;Xue, Jie;Hu, Man;Zheng, Jinsong;Wang, Xiaohui

    Objective : To investigate the clinical value in detecting occult primary tumors with 18F-FDG PET-CT whole body imaging. Methods : 120 patients with unknown primary origin were referred for 18F-FDG PET-CT whole body imaging. All patients were performed 18F-FDG PET-CT whole body scan. PET-CT images were interpreted by visual inspection and semi-quantitative analysis (standardized uptake value, SUV). Histopathological and formal clinical follow-up findings were used to assess the value of FDG PET-CT. Results: FDG PET-CT was able to detect the primary tumor in 54/120 patients (42.5%). The primary tumors were confirmed by histopathologic and formal clinical follow-up findings, and located in the head and neck (n = 17), the lung (n = 19), the breast (n = 2), the esophagus (n = 1), the stomach (n = 2), the bile ducts (n = 1), the pancreas (n = 3), the co1on (n = 3), the ovary (n = 2), the prostate (n = l), others (n = 3). FDG PET results were proved false positive in 9 patients (7.5%), ...


Mots clés : Cancer (général); Dépistage, diagnostic et pronostic (Essais de technologies et de biomarqueurs dans un contexte clinique)

Recherche de publications

Recherche avancée

Widget

 

Archives

Formulaire d’abonnement

Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :

S'abonner

Sources

Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :

Accéder au portail des sources du NBC

Foire aux questions

Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :

Accéder à la F.A.Q.